公开(公告)号：US20250066369A1

公开(公告)日：2025-02-27

申请号：US18726919

申请日：2023-01-06

Applicant: NodThera Limited

Inventor： Mark G. BOCK ,  David HARRISON ,  Jane E. SCANLON

IPC: C07D487/04 ,  A61K31/5025 ,  A61K31/506 ,  C07D471/04 ,  C07D491/048 ,  C07D495/04 ,  C07D519/00

Abstract: The present disclosure relates to compounds of Formula (III): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.

公开(公告)号：US20250066328A1

公开(公告)日：2025-02-27

申请号：US18784100

申请日：2024-07-25

Applicant: Gilead Sciences, Inc.

Inventor： Jonah J. Chang ,  Jayaraman Chandrasekhar ,  Kevin S. Currie ,  Stephen D. Holmbo ,  Jesse M. Jacobsen ,  David L. Kukla ,  Seung H. Lee ,  Yasamin Moazami ,  Leena B. Patel ,  Thomas J. Paul ,  Stephane Perreault ,  Patrick J. Salvo ,  Jennifer A. Treiberg ,  Heath A. Weaver

IPC: C07D401/14 ,  A61K9/00 ,  A61K9/02 ,  A61K9/20 ,  A61K9/48 ,  A61K31/501 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5383 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/26 ,  A61K47/36 ,  A61K47/38 ,  A61K47/44 ,  C07D403/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D491/048 ,  C07D498/04

Abstract: Provided herein is a compound of Formula (I): or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or deuterated analog thereof, a pharmaceutical composition comprising a compound of the present disclosure, together with a pharmaceutically acceptable excipient thereof, and a method of treating cancer with the same.

公开(公告)号：US20250059165A1

公开(公告)日：2025-02-20

申请号：US18789815

申请日：2024-07-31

Applicant: Boehringer Ingelheim International GmbH

Inventor： Jens WILLWACHER ,  Florian Paul Christian BINDER ,  Georg DAHMANN ,  Sandra Ruth HANDSCHUH ,  Sophia Astrid REINDL ,  James Young Soo YANG HAMILTON

IPC: C07D401/14 ,  A61K31/4545 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/519 ,  A61K45/06 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  C07D491/048 ,  C07D498/04

Abstract: The present disclosure provides certain piperidinylpyridinylcarbonitrile derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl-peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferase-like protein (QPCTL), and are therefore useful for the treatment of diseases treatable by inhibition of QPCT/L. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.

公开(公告)号：US20250057042A1

公开(公告)日：2025-02-13

申请号：US18908952

申请日：2024-10-08

Applicant: Samsung Electronics Co., Ltd. ,  Samsung SDI Co., Ltd.

Inventor： Seungjae LEE ,  Byungku KIM ,  Youngkwon KIM ,  Changwoo KIM ,  Hyungsun KIM ,  Changju SHIN ,  Eunsun YU ,  Byoungki CHOI ,  Kyuyoung HWANG

IPC: H10K85/60 ,  C07D405/14 ,  C07D491/048 ,  C09K11/06 ,  H10K50/11 ,  H10K50/15 ,  H10K50/16 ,  H10K50/17 ,  H10K50/18 ,  H10K85/30 ,  H10K101/10

Abstract: A condensed-cyclic compound represented by Formula 1A: wherein in Formula 1A, groups, substituents, and variables are the same as defined in the specification.

公开(公告)号：US20250051345A1

公开(公告)日：2025-02-13

申请号：US18718953

申请日：2022-12-12

Applicant: Novartis AG

Inventor： Simon Krautwald ,  Jianliang Lu ,  James Anthony Neef ,  Hye-Yeon Park ,  Tejaskumar Pankajbhai Pathak ,  Amir Masoud Sadaghiani ,  Xilin Zhou

IPC: C07D491/048 ,  A61K31/444

Abstract: The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as Cav1.2 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder. ADHD, Phelan-Mc-Dermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease. Brugada Syndrome. Short QT syndrome, or early repolarization syndrome.

公开(公告)号：US20250034114A1

公开(公告)日：2025-01-30

申请号：US18917653

申请日：2024-10-16

Applicant: Novartis AG

Inventor： Xiaobin Ge ,  Henri Mattes ,  Zhicong Shi ,  Mei Xia ,  Ning Ye

IPC: C07D401/12 ,  A61K45/06 ,  C07D491/048

Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of formula (I): wherein R1, R2, R3, R4 and R5 are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.

公开(公告)号：US20250011323A1

公开(公告)日：2025-01-09

申请号：US18776612

申请日：2024-07-18

Applicant: Omeros Corporation

Inventor： Neil S. Cutshall ,  Jennifer Lynn Gage ,  Do Yeon Kwon ,  Thomas L. Little ,  Markus Metz ,  Peter Kurt Nollert von Specht ,  Jennifer Tsoung ,  Jeremiah H. Nguyen ,  Melinda Davis ,  Robert Huerta Lemus ,  Santosh Kumar Keshipeddy ,  Sara Rebecca Goldstein

IPC: C07D471/04 ,  C07D239/545 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D491/048 ,  C07D495/04 ,  C07D519/00

Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.

公开(公告)号：US20250002499A1

公开(公告)日：2025-01-02

申请号：US18422517

申请日：2024-01-25

Applicant: Novartis AG

Inventor： Sung David C. Kim ,  Zaixing Li ,  Chui Lu ,  Danuta Lubicka ,  James Neef ,  Hye-Yeon Park ,  Tejaskumar Pankajbhai Pathak ,  Amir Masoud Sadaghiani ,  Xilin Zhou

IPC: C07D491/048 ,  C07D221/04

Abstract: The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as CaV1.22 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, or early repolarization syndrome.

公开(公告)号：US12171143B2

公开(公告)日：2024-12-17

申请号：US17417209

申请日：2020-01-22

Applicant: LT MATERIALS CO., LTD.

Inventor： Yun-Ji Lee ,  Min-Ji Park ,  Won-Jang Jeong

IPC: C07D491/04 ,  C07D491/048 ,  C07D495/04 ,  H10K85/60 ,  H10K50/16 ,  H10K50/18

Abstract: The present application relates to a compound represented by Chemical Formula 1, an organic optoelectronic diode and a display device. In Chemical Formula 1, each substituent has the same definition as in the specification.

公开(公告)号：US20240398784A1

公开(公告)日：2024-12-05

申请号：US18685357

申请日：2022-09-26

Applicant: Merck Sharp & Dohme LLC

Inventor： Peter H. Fuller ,  Anmol Gulati ,  Solomon D. Kattar ,  Mitchell H. Keylor ,  Kaila A. Margrey ,  Luis Torres ,  Xin Yan

IPC: A61K31/472 ,  A61K31/4725 ,  A61K31/5377 ,  C07D217/22 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/12 ,  C07D491/048

Abstract: The present invention is directed to certain 2-aminoquinzaoline derivatives of Formula (I): Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, and R3 are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.